A Bristol Myers (BMY) Squibb treatment of pancreatic cancer was granted FDA orphan designation, according to a post to the agency’s website.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Private Markets: Anthropic projects $70B in revenue in 2028
- Bristol Myers reaches $239M settlement over Otezla, Zeposia, Reuters reports
- How MRK, ABBV, and BMY Could Rescue Investor Portfolios in a Downturn
- 3 Stocks to Sell Now, According to Top-Rated Analysts – November 3, 2025
- Balanced Outlook on Bristol-Myers Squibb: Strong Q3 Performance Amid ADEPT-2 Trial Concerns